Darovasertib

N/A

Report date: 2026/03/17 20:00:15
NMEFirst In Class

Base Information

Drug NameDarovasertib
Drug Alias NameLXS-196IDE-196NVP-LXS196
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtein kinase C inhibitors
TargetsProtein kinase C
Therapy Area/IndicationsUveal melanomaSkin MelanomaSolid tumours +[4
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[22
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesIdeaya Biosciences Inc
Inactive CompaniesNovartis Pharma Ag
Active IndicationsUveal melanomaSkin MelanomaSolid tumours +[4
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A